Aller au contenu principal
Accès ouvert déclaré 2026 book-chapter

Perspective Chapter: The Use of Fluorescence in Ovarian Cancer Surgery

0Citations signalées, ce qui n’est pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés

Le résumé fourni par la source

In this modern era, one might find several innovative treatments that are constantly updating themselves and are thus shaping the future of therapy in ovarian cancer patients. The major challenge confronting the clinician is selecting from a range of established and traditional treatment methods (such as chemotherapy or immunotherapy) versus new nanotechnology advancements and gene therapy, which have newly emerged but are evolving rapidly. In terms of surgery, modern-day updates can offer a more precise and up-to-date treatment, with various options to adapt the technique to the patient’s particular needs and indications. An excellent example of surgical modern-day enhancement is fluorescence. Given that complete cytoreduction is a vital prognostic element in advanced epithelial ovarian cancer, surgery enhanced by fluorescence using fluorescent markers might significantly improve the identification of microscopic disease and the prognosis of surgical treatment. Additionally, CD24, a receptor on the cell surface, presents overexpression in 70% of solid tumors and could serve as a predictive and therapeutic biomarker for epithelial ovarian cancer. Recent preclinical studies have demonstrated that CD24-targeted imaging agents enhance tumor removal and noninvasive fluorescence visualization in orthotopic patient-derived xenograft models of epithelial ovarian cancer. Additionally, fluorescence-guided cytoreductive surgery targeting human epidermal growth factor receptor two or folate receptor alpha has demonstrated feasibility in both animal models and individuals with epithelial ovarian cancer. In conclusion, fluorescence-guided surgery may enhance the diagnosis of ovarian cancer micrometastasis and sentinel lymph nodes. More precise future research is required to determine whether the use of this method improves patient outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Perspective Chapter: The Use of Fluorescence in Ovarian Cancer Surgery
Date Crossref
07/01/2026
Éditeur
IntechOpen
Type
book-chapter

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les sujets associés

Cancer Research and TreatmentsOvarian cancer diagnosis and treatmentNanoplatforms for cancer theranostics

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.